Identification and characterization of novel small-molecule inhibitors against hepatitis delta virus replication by using docking strategies

Hepatitis Monthly

Volumn 11, Issue 10, 2011, Pages 803-809

  Singh, Sarita ^a,b   Gupta, Sunil Kumar ^a,b   Nischal, Anuradha ^b   Khattri, Sanjay ^b   Nath, Rajendra ^b   Pant, Kamlesh Kumar ^b   Seth, Prahlad Kishore ^a  

^a Bioinformatics centre   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Antiviral agents; Hepatitis delta virus; RNA viruses

Indexed keywords

3 [(4,7 DICHLORO 1,3 BENZOXAZOL 2 YL)METHYLAMINO] 5 ETHYL 6 METHYLPYRIDIN 2(H) ONE; ANTIVIRUS AGENT; HEPATITIS DELTA ANTIGEN; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING FREE ENERGY; BINDING KINETICS; COMPUTER PROGRAM; DRUG BINDING SITE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; HEPATITIS B VIRUS; HYDROGEN BOND; ISOELECTRIC POINT; MOLECULAR DOCKING; MOLECULAR WEIGHT; PROTEIN TARGETING; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 80355139413     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.1387     Document Type: Article

References (43)

1. Taylor JM. Hepatitis delta virus. Virology. 2006;344(1):71-76.
2. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003.
3. Lai MM. The molecular biology of hepatitis delta virus. Annu Rev Biochem. 1995;64:259-286.
4. Taylor JM. The structure and replication of hepatitis delta virus. Annu Rev Microbiol. 1992;46:253-276.
5. Gudima S, Chang J, Moraleda G, Azvolinsky A, Taylor J. Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol. 2002;76(8):3709-3719.
6. Lo K, Hwang SB, Duncan R, Trousdale M, Lai MM. Characterization of mRNA for hepatitis delta antigen: exclusion of the full-length antigenomic RNA as an mRNA. Virology. 1998;250(1):94-105.
7. Bergmann KF, Gerin JL. Antigens of hepatitis delta virus in the liver and serum of humans and animals. J Infect Dis. 1986;154(4):702-706.
8. Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol. 1986;58(3):945-950.
9. Pohl C, Baroudy BM, Bergmann KF, Cote PJ, Purcell RH, Hoofnagle J, et al. A human monoclonal antibody that recognizes viral polypeptides and in vitro translation products of the genome of the hepatitis D virus. J Infect Dis. 1987;156(4):622-629.
10. Roggendorf M, Pahlke C, Bohm B, Rasshofer R. Characterization of proteins associated with hepatitis delta virus. J Gen Virol. 1987;68 (Pt 11):2953-2959.
11. Casey JL, Gerin JL. Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. J Virol. 1995;69(12):7593-7600.
12. Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature. 1996;380(6573):454-456.
13. Polson AG, Ley HL, 3rd, Bass BL, Casey JL. Hepatitis delta virus RNA editing is highly specific for the amber/W site and is suppressed by hepatitis delta antigen. Mol Cell Biol. 1998;18(4):1919-1926.
14. Kuo MY, Chao M, Taylor J. Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol. 1989;63(5):1945-1950.
15. Chao M, Hsieh SY, Taylor J. Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol. 1990;64(10):5066-5069.
16. Glenn JS, White JM. trans-dominant inhibition of human hepatitis delta virus genome replication. J Virol. 1991;65(5):2357-2361.
17. Singh S, Gupta SK, Nischal A, Khattri S, Nath R. Comparative Modeling Study of the 3-D Structure of Small Delta Antigen Protein of Hepatitis Delta Virus. J Comput Sci Syst Biol. 2010;3:1-4.
18. Bohacek RS, McMartin C, Guida WC. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev. 1996;16(1):3-50.
19. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature. 2004;432(7019):855-861.
20. Walters WP, Stahl MT, Murcko MA. Virtual screening-an overview. Drug Discov Today. 1998;3(4):160-178.
21. Schneider G, Clement-Chomienne O, Hilfiger L, Schneider P, Kirsch S, Bohm HJ, et al. Virtual Screening for Bioactive Molecules by Evolutionary De Novo Design Special thanks to Neil R. Taylor for his help in preparation of the manuscript. Angew Chem Int Ed Engl. 2000;39(22):4130-4133.
22. Drewry DH, Stanley Young S. Approaches to the design of combinatorial libraries. Chemometr Intell Lab. 1999;48(1):1-20.
23. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 2002;1(11):882-894.
24. Lahana R. How many leads from HTS? Drug Discov Today. 1999;4(10):447-448.
25. Miller JL. Recent developments in focused library design: targeting gene-families. Curr Top Med Chem. 2006;6(1):19-29.
26. Willett P. Similarity-based virtual screening using 2D fingerprints. Drug Discov Today. 2006;11(23-24):1046-1053.
27. Mason JS, Good AC, Martin EJ. 3-D pharmacophores in drug discovery. Curr Pharm Des. 2001;7(7):567-597.
28. Schneider G, Bohm HJ. Virtual screening and fast automated docking methods. Drug Discov Today. 2002;7(1):64-70.
29. Winkler DA. The role of quantitative structure-activity relationships (QSAR) in biomolecular discovery. Brief Bioinform. 2002;3(1):73-86.
30. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov. 2005;4(8):649-663.
31. Longini IM, Jr., Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, et al. Containing pandemic influenza at the source. Science. 2005;309(5737):1083-1087.
32. Hess B, Kutzner C, Van Der Spoel D, Lindahl E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4(3):435-447.
33. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-2791.
34. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461.
35. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33(Web Server issue):W363-7.
36. Moda TL, Torres LG, Carrara AE, Andricopulo AD. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics. 2008;24(19):2270-2271.
37. Oprea TI, Davis AM, Teague SJ, Leeson PD. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci. 2001;41(5):1308-1315.
38. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1999;1(1):55-68.
39. Jitendra S, Vinay R. Structure based drug designing of a novel antiflaviviral inhibitor for nonstructural 3 protein. Bioinformation. 2011;6(2):57-60.
40. Adinarayana KP, Devi RK. Protein-Ligand interaction studies on 2, 4, 6- trisubstituted triazine derivatives as anti-malarial DHFR agents using AutoDock. Bioinformation. 2011;6(2):74-77.
41. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443(7107):45-49.
42. Wei DQ, Zhang R, Du QS, Gao WN, Li Y, Gao H, et al. Anti-SARS drug screening by molecular docking. Amino Acids. 2006;31(1):73-80.
43. Chang MW, Ayeni C, Breuer S, Torbett BE. Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One. 2010;5(8):e11955.